Drug intelligence / Profile preview

neldaleucel

Development stage: Phase 1
Lead developer: Marker Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Neldaleucel (MT-601) is an autologous, non-genetically modified, multi-tumor-associated antigen (multiTAA)-specific T cell therapy developed by Marker Therapeutics for the treatment of pancreatic adenocarcinoma. Utilizing the proprietary MAR-T (Multi-Antigen Recognizing T cell) platform, the therapy consists of cytotoxic T lymphocyte lines that simultaneously target six tumor-associated antigens highly expressed in pancreatic cancer: PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, and WT1. Unlike CAR-T or TCR-T therapies, neldaleucel does not require genetic engineering, which may reduce manufacturing complexity and improve safety by avoiding insertional mutagenesis. The therapy is currently being evaluated in the Phase 1 PANACEA study in combination with front-line chemotherapy for patients with newly diagnosed locally advanced unresectable or metastatic pancreatic adenocarcinoma.

Brand names: MultiTAA
Other names: MT-601MT601MT 601

Targets

WT1 (Wilms tumor protein)SSX2 (Synovial sarcoma X breakpoint protein 2)PRAME (Preferentially expressed antigen in melanoma)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)pHLA (Human leukocyte antigen class I and class II peptide-presenting complexes)BIRC5 (Survivin)MAGEA4 (Melanoma-associated antigen A4)

Beyond the preview

Go deeper on neldaleucel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on neldaleucel.

Explore the full profile